Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus-infected patients with renal impairment: results from a 7-year, multicentre retrospective cohort study.

Pietro LamperticoThomas BergMaria Buti FerretAnita PathilJoerg PetersenStephen D RyderFabien ZoulimIrina BotrosJohn F FlahertyBelinda JumpMarjoleine L Op den BrouwAnna van TroostenburgHeribert Ramrothnull null

Published in: Alimentary pharmacology & therapeutics (2020)

Overall safety was similar for TDF vs ETV (both subgroups). Given that renal tubular dysfunction occurred with TDF and not with ETV, renal safety concerns may be greater with TDF in CHB patients with RI.

Keyphrases

hepatitis b virus
acute lymphoblastic leukemia
clinical trial
oxidative stress
liver failure
randomized controlled trial
cross sectional
combination therapy
replacement therapy